Economic burden associated with the management of cervical cancer, cervical dysplasia and genital warts in Belgium

Journal of Medical Economics

Volumn 11, Issue 1, 2008, Pages 135-150

  Annemans, Lieven ^a   Rémy, Vanessa ^b   Lamure, Emilie ^c   Spaepen, Erik ^d   Lamotte, Mark ^d   Muchada, Jean Paul ^e   Largeron, Nathalie ^b  

^a GHENT UNIVERSITY   (Belgium)

^b SANOFI PASTEUR   (France)

^c IMS HEOR   (France)

^d IMS Health   (Belgium)

^e Sanofi Pasteur MSD   (Belgium)

Author keywords

Belgium; Cervical cancer; Cost; Genital warts; Human papillomavirus

Indexed keywords

ADULT; ARTICLE; BELGIUM; CONDYLOMA ACUMINATUM; COST BENEFIT ANALYSIS; DATA BASE; ECONOMIC ASPECT; FEMALE; HEALTH CARE SYSTEM; HUMAN; MAJOR CLINICAL STUDY; OUTCOME ASSESSMENT; RETROSPECTIVE STUDY; SOCIETY; UTERINE CERVIX CANCER; UTERINE CERVIX CARCINOMA IN SITU; UTERINE CERVIX DYSPLASIA; WART VIRUS;

ADOLESCENT; ADULT; BELGIUM; CONDYLOMATA ACUMINATA; COSTS AND COST ANALYSIS; FEMALE; HEALTH EXPENDITURES; HUMANS; MIDDLE AGED; MODELS, ECONOMETRIC; PAPILLOMAVIRUS INFECTIONS; RETROSPECTIVE STUDIES; UTERINE CERVICAL DYSPLASIA; UTERINE CERVICAL NEOPLASMS; YOUNG ADULT;

EID: 42949160517     PISSN: 13696998     EISSN: None     Source Type: Journal    
DOI: 10.3111/13696990801961611     Document Type: Article

References (38)

1. Arbyn M, Autier P, Ferlay J. Burden of cervical cancer in the 27 member states of the European Union: estimates for 2004. Annals of Oncology 2007 ; 18 : 1425-1427.
2. The UK Collaborative Group for HIV and STI Surveillance. Testing Times. HIV and Other Sexually Transmitted Infections in the United Kingdom: 2007. London, UK: Health Protection Agency, Centre for Infections, 2007 .
3. Hulstaert F, Arbyn M, Huybrechts M et al. Dépistage du cancer du col de l'utérus et recherche du papillomavirus humain (HPV). Health Technology Assessment (HTA). KCE report 38B. Brussels, Belgium: Centre fédéral d'expertise des soins de santé (KCE), 2006.
4. Ferlay J, Bray F, Pisani P et al. GLOBOCAN 2000. Cancer Incidence, Mortality and Prevalence Worldwide. IARC CancerBase No. 5, version 2.0 Lyon, France: IARC Press, 2004.
5. Von Krogh G. Management of anogenital warts (condylomata acuminata). European Journal of Dermatology 2001 ; 11 : 598-603 .
6. Walboomers JMM, Jacobs MV, Manos M et al. Human papillomavirus: a necessary cause of invasive cervical cancer world-wide. Journal of Pathology 1999 ; 189 : 12-19 .
7. Munoz N, Bosch FX, de Sanjose S et al. Epidemiologic classification of human papillomavirus types associated with cervical cancer. New England Journal of Medicine 2003 ; 348 : 518-527 .
8. Laara E, Day NE, Hakama M. Trends in mortality from cervical cancer in the Nordic countries: association with organised screening programmes. Lancet 1987 ; 1 : 1247-1249 .
9. International Agency for Research on Cancer. Cervix Cancer Screening. IARC Handbooks of Cancer Prevention. Vol. 10. Lyon, France: IARC Press, 2005 .
10. Arbyn M, Van Oyen H. Cervical cancer screening in Belgium. European Journal of Cancer 2000 ; 36 : 2191-2197 .
11. Arbyn M, Van Oyen H. Analysis of individual health insurance data pertaining to pap smears, colposcopies, biopsies and surgery on the uterine cervix (Belgium, 1996-2000). Epidemiology, October 2004. Brussels, Belgium: Scientific Institute of Public Health, SIPH/EPI Report N 2004-021 .
12. Fenton KA, Lowndes CM. Recent trends in the epidemiology of sexually transmitted infections in the European Union. Sexually Transmitted Infections 2004 ; 80 : 255-263 .
13. Koutsky L. Epidemiology of genital human papillomavirus infection. American Journal of Medicine 1997 ; 102 : 3-8 .
14. Kjaer SK, Tran TN, Sparen P et al. The burden of genital warts: a study of nearly 70,000 women from the general female population in the 4 Nordic countries. Journal of Infectious Diseases 2007 ; 196 : 1447-1454 .
15. McMillan A. The management of difficult anogenital warts. Sexually Transmitted Diseases 1999 ; 75 : 192-194 .
16. Lacey CJN, Lowndes CM, Shah KV. Chapter 4: Burden and management of non-cancerous HPV-related conditions: HPV-6/11 disease. Vaccine 2006 ; 24 (Suppl 3) : S35-S41.
17. Brown RE, Breugelmans JG, Theodoratou D et al. Costs of detection and treatment of cervical cancer, cervical dysplasia and genital warts in the UK. Current Medical Research and Opinion 2006 ; 22 : 663-670.
18. Arveux P, Benard S, Bouee S et al. Invasive cervical cancer treatment costs in France. Bulletin du Cancer 2007 ; 94 : 219-224 .
19. Bergeron C, Breugelmans JG, Bouée S et al. [Cervical cancer screening and associated treatment costs in France.] Gynécologie, Obstétrique & Fertilité 2006 ; 34 : 1036-1042 [in French] .
20. Monsonégo J, Breugelmans JG, Bouée S et al. [Anogenital warts incidence, medical management and costs in women consulting gynaecologists in France]. Gynécologie, Obstétrique & Fertilité 2007 ; 35 : 107-113 [in French].
21. National Center for Health Statistics. International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM). Available at: http://www.cdc.gov/nchs/about/otheract/icd9/abticd9.htm [accessed July 2007].
22. Pirson M, Dramaix M, Leclercq P et al. Analysis of cost outliers within APR-DRGs in a Belgian general hospital: two complementary approaches. Health Policy 2006 ; 76 : 13-25 .
23. Analyse économique des coûts du cancer en France: impact sur la qualité de vie, prévention, dépistage, soins, recherche. «Etudes et expertises » éditée par l'Institut National du Cancer. Mars 2007 .
24. National Institute for Statistics. Statistics Belgium. Available at: http://www.statbel.fgov.be [accessed July 2007] .
25. National Institute for Statistics. Available at: http://statbel.fgov.be/ downloads/lfs1004-2004-fr.xls [accessed July 2007] .
26. National Institute for Health Insurance (INAMI/RIZIV). Available at: http://www.riziv.be [accessed July 2007] .
27. Castellsague X, De San José S, Aguado T et al. HPV and cervical cancer in the world, 2007 report. Vaccine 2007 ; 25 : C27-C219 .
28. De Schrijver K. Epidemiologisch bulletin van de vlaamse gemeenschap, De epidemiologie van seksueel overdraagbare aandoeningen in belgië. NR 45 2003/3 .
29. Belgian Cancer Registry Foundation. Available at: http://www. kankerregister.be/ [accessed December 2007] .
30. Available at: http://www.onssrszlss.fgov.be/Onssrsz/FR/Statistics/ Brochures/Green/xls/rrn-2007-1-fr.xls[accessed July 2007] .
31. The National Centre for Screening Monitoring Fourth Report. Rivista dell'Associazione italiana di epidemiologia. Anno 30 (1) 2006 Supplemento 3 .
32. Direction générale statistique et information économique. Population et ménages, Population totale et belge. 2004.
33. Wolstenholme JL, Whynes DK. Stage-specific treatment costs for cervical cancer in the United Kingdom. European Journal of Cancer 1998 ; 34 : 1889-1893.
34. Thiry N, Lambert ML, Cleemput I et al. Vaccination HPV pour la prévention du cancer du col de l'utérus en Belgique: Health Technology Assessment. KCE report 64B. Brussels, Belgium: Centre fédéral d'expertise des soins de santé (KCE), 2007 .
35. Garland SM, Hernandez-Avila M, Wheeler CM et al. Quadrivalent vaccine against human papillomavirus to prevent anogenital diseases. New England Journal of Medicine 2007 ; 356 : 1928-1943.
36. The FUTURE. II Study Group. Quadrivalent vaccine against human papillomavirus to prevent high-grade cervical lesions. New England Journal of Medicine 2007 ; 356 : 1915-1927 .
37. Bergeron C, Largeron N, McAllister R et al. Cost-effectiveness analysis of the introduction of a quadrivalent human papillomavirus vaccine in France International Journal of Technology Assessment in Health Care 2008 ; 24 : 10-19 .
38. Elbasha EH, Dasbach EJ, Insinga RP. Model for assessing human papillomavirus vaccination strategies Emerging Infectious Diseases 2007 ; 13 : 28-41.